WEBULL
News
SVRA
6.06
-0.82%
-0.05
Savara Is Maintained at Overweight by Wells Fargo
Dow Jones · 8h ago
Savara Price Target Raised to $9.00/Share From $7.00 by Wells Fargo
Dow Jones · 8h ago
Wells Fargo Maintains Overweight on Savara, Raises Price Target to $9
Benzinga · 8h ago
Wells Fargo Reaffirms Their Buy Rating on Savara (SVRA)
TipRanks · 10h ago
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
Barchart · 1d ago
Weekly Report: what happened at SVRA last week (1208-1212)?
Weekly Report · 3d ago
Savara (SVRA): Valuation Check After European Patent Win for MOLBREEVI in Autoimmune PAP
Simply Wall St · 3d ago
Savara (SVRA) Is Up 8.9% After European Patent Boost For MOLBREEVI Nebulized Therapy
Simply Wall St · 6d ago
Savara Inc. Unveils Corporate Presentation on Advancing Therapies for Rare Respiratory Diseases
Reuters · 12/11 13:28
Savara announces EPO intention to grant Molbreevi patent application
TipRanks · 12/11 13:16
Savara Inc. Announces EPO Intention to Grant Patent for Liquid Formulation of MOLBREEVI
Reuters · 12/11 13:05
SAVARA ANNOUNCES EUROPEAN PATENT OFFICE (EPO) INTENDS TO GRANT A PATENT FOR THE LIQUID FORMULATION OF MOLBREEVI*
Reuters · 12/11 13:05
Savara’s MOLBREEVI: A Promising Solution for aPAP with Blockbuster Potential
TipRanks · 12/10 12:36
Weekly Report: what happened at SVRA last week (1201-1205)?
Weekly Report · 12/08 09:23
Savara (SVRA): Valuation Check After New European Patent Win and Rising Conference-Driven Investor Interest
Simply Wall St · 12/03 09:21
Savara Inc. ticks higher amid takeover speculation
Seeking Alpha · 12/02 19:39
Savara rumor highlighted in Betaville blog
TipRanks · 12/02 19:25
Savara issues patent for Molbreevi from European Patent Office
TipRanks · 12/02 13:36
Savara, PARI Granted European Patent Titled 'Drug-Device Combination Comprising a Liquid Solution and a Nebulizer for Aerosolization of the Liquid Solution.'
Benzinga · 12/02 13:31
Savara Inc. Unveils New Therapies Targeting Rare Respiratory Diseases
Reuters · 12/02 13:22
More
Webull provides a variety of real-time SVRA stock news. You can receive the latest news about Savara Inc through multiple platforms. This information may help you make smarter investment decisions.
About SVRA
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.